Vorozole

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Vorozole
Vorozole.svg
Clinical data
ATC code
Pharmacokinetic data
Bioavailability Very high
Metabolism Hepatic
Biological half-life 8 hours
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
Formula C16H13ClN6
Molar mass 324.768 g/mol
3D model (Jmol)
 NYesY (what is this?)  (verify)

Vorozole is an imidazole based competitive inhibitor of the aromatase enzyme. It underwent clinical testing for evaluation for use as an antineoplastic agent; however it was withdrawn from testing when no difference was detected in the duration of median survival as compared to the progestational agent megestrol acetate and research instead focused on the other third generation aromatase inhibitors anastrozole, letrozole and exemestane. The enzyme is selective.[1]

References[edit]

  1. ^ Goss PE (1998). "Pre-clinical and clinical review of vorozole, a new third generation aromatase inhibitor" (PDF). Breast Cancer Res. Treat. 49. Suppl 1: S59–65; discussion S73–7. doi:10.1023/a:1006052923468. PMID 9797019.